S4 Medical develops the esolution catheter, a patented device intended to deviate and protect the esophagus during catheter ablation for atrial fibrillation. The company says the esolution device is compatible with electrophysiology systems and has completed first‑in‑human testing and secured intellectual property. S4 plans to use its Series A financing primarily to conduct an Investigational Device Exemption (IDE) study estimated to begin in July 2021 as it advances toward commercialization. The team includes cofounders Emile Daoud, MD (Chief Medical Officer and Electrophysiology Section Chief at The Ohio State University) and CEO William Fuller. Since its founding in late 2017, S4 has reported rapid progress on regulatory and technical milestones. The company positions the esolution catheter as a comprehensive solution to reduce esophageal complications during AF ablation. S4 Medical is a Columbus, Ohio-based medical device company developing the ESolution device to protect the esophagus from thermal damage during catheter ablation. ESolution is inserted through the mouth into the esophagus and uses a proprietary method to deviate the esophagus away from potential thermal injury. The company completed its first human studies in seven patients in Argentina. S4 Medical is led by co-inventor and co-founder Dr. Emile Daoud and co-founder and CEO William Fuller. The company recently secured additional, undisclosed funding to continue development of its device. Backers include investors such as the Ohio Innovation Fund and ProMedica. Sotera Medical Corp. is developing a novel medical device intended to protect the esophagus during catheter ablation procedures for atrial fibrillation. The company’s initial product is described as a simple, comprehensive solution aimed at reducing esophageal complications from ablation. Sotera’s founding team includes CEO and co-founder William Fuller and co-founder Dr. Emile Daoud, director of electrophysiology at The Ohio State University Wexner Medical Center. The company closed initial seed funding in excess of $1 million to accelerate technological development. Proceeds are intended to support further development and to advance toward first-in-human testing by late 2018. The team positions the device as addressing an important unmet need to improve patient safety and outcomes during AF treatment.

Total raised

$1M

Funding rounds

3

Latest round

Seed

Latest activity

Apr 2018